Atara Biotherapeutics Adds Independent Director to Board
I'm LongbridgeAI, I can summarize articles.Atara Biotherapeutics appointed Brian Cherry as an independent director and Audit Committee member, granting him restricted stock units. The company also held its 2026 annual meeting, re-electing directors, approving equity plan increases, and ratifying Deloitte as auditor. Analysts rate ATRA a Hold with a $10 price target. Spark AI rates it Neutral due to weak financials despite supportive technicals.
Atara Biotherapeutics ( (ATRA) ) has shared an announcement.
On June 11, 2026, Atara Biotherapeutics appointed Brian Cherry as a Class I independent director and member of its Audit Committee, granting him 24,000 restricted stock units vesting over three years and standard non-employee director compensation. The company also executed its standard indemnification agreement with Cherry, underscoring its adherence to governance and board independence practices.
Atara held its 2026 annual meeting of stockholders on June 9, 2026, where shareholders re-elected AnhCo Nguyen and Nachi Subramanian as directors through the 2029 meeting and approved, on an advisory basis, the compensation of the company’s named executive officers. Investors also approved an increase of 400,000 shares under the 2024 Equity Incentive Plan and ratified Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year, signaling continued support for Atara’s governance and equity-based compensation strategy.
The most recent analyst rating on (ATRA) stock is a Hold
with a $10.00 price target.
To see the full list of analyst forecasts on Atara Biotherapeutics stock,
see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Overall score is held down primarily by weak financial performance (sharp revenue contraction, ongoing losses, negative equity, and persistent cash burn). Technicals are supportive due to strong momentum and price above major moving averages, but overbought RSI limits confidence. Corporate events are mixed, with regulatory pathway improvement offset by delisting risk, while valuation is constrained by loss-making fundamentals and no dividend support.
To see Spark’s full report on ATRA stock,
click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutics, including cell-based and immunotherapy products, for serious diseases. The company operates in the biopharmaceutical sector and targets unmet medical needs, positioning itself within a competitive landscape of innovative drug developers.
Average Trading Volume: 1,407,074
Technical Sentiment Signal: Hold
Current Market Cap: $94.25M
Learn more about ATRA stock on TipRanks’ Stock Analysis page.